Company Overview

cbdMD, Inc. (YCBD) is a U.S.-based consumer wellness company focused on the development, manufacturing, and marketing of cannabidiol (CBD) and hemp-derived products. The company operates within the consumer health and wellness, nutraceutical, and pet wellness industries, offering a portfolio that includes tinctures, gummies, topicals, capsules, and pet-focused formulations. Its products are formulated using U.S.-grown hemp and are marketed as THC-free or compliant with federal hemp regulations, depending on the product line.

The company’s primary revenue drivers are branded CBD consumer products sold through e-commerce, third-party online marketplaces, and select wholesale and retail channels. cbdMD positions itself around product quality, in-house formulation, and transparent testing standards, emphasizing consistent dosing and compliance. Founded in 2015, the company grew rapidly during the early expansion of the U.S. CBD market and became publicly traded in 2018. Since 2022, cbdMD has undergone restructuring efforts following industry-wide pricing pressure, regulatory uncertainty, and declining CBD category demand. The company currently trades on the OTC market following its delisting from NYSE American; the timing and circumstances of the delisting are consistently reported, though long-term strategic outcomes remain uncertain.

Business Operations

cbdMD generates revenue primarily through the sale of branded consumer products under its core operating brands cbdMD, Paw CBD, and ATRx. The cbdMD brand focuses on human wellness products such as oils, softgels, gummies, and topical creams. Paw CBD targets the pet health segment with CBD-based tinctures, chews, and topical solutions for dogs and cats. ATRx is positioned as a functional sports nutrition and performance recovery line incorporating CBD and non-CBD ingredients.

Operations are predominantly domestic, with manufacturing and formulation activities supported through third-party contract manufacturers while quality control, product development, and branding remain internal. The company sells directly to consumers through its owned e-commerce platforms and maintains distribution relationships with online marketplaces and select brick-and-mortar retailers. cbdMD does not disclose material joint ventures; however, it has historically relied on athlete endorsements and brand ambassadors as part of its go-to-market strategy. International sales have been limited and inconsistent, with no verified large-scale overseas operating subsidiaries currently disclosed.

Strategic Position & Investments

Strategically, cbdMD has focused on cost containment, SKU rationalization, and balance sheet preservation amid a prolonged downturn in the U.S. CBD market. Growth initiatives in recent years have emphasized higher-margin products, repeat-purchase customer segments, and the pet wellness category, which has shown relatively stronger demand compared to human CBD products. The company has also sought to reduce reliance on promotional discounting and to streamline marketing spend.

cbdMD has made selective past acquisitions to expand its brand portfolio, most notably ATRx, which added a sports nutrition and recovery dimension to its offerings. No material acquisitions have been publicly confirmed in the most recent reporting periods, and capital investment activity appears constrained. While management has referenced interest in adjacent wellness categories and functional health products, the extent of investment in emerging technologies or new regulated cannabinoids cannot be conclusively verified based on available public disclosures.

Geographic Footprint

The company’s headquarters and primary operations are located in the United States, which represents the vast majority of its revenue and operational focus. cbdMD’s customer base is predominantly U.S.-based, supported by domestic fulfillment and marketing infrastructure. Product sourcing relies on U.S.-grown hemp, aligning with federal regulatory requirements.

Internationally, cbdMD has previously marketed products into select foreign jurisdictions through distributors or online channels; however, sustained international operations or material revenue contributions from outside the U.S. are not consistently disclosed in recent public filings. As a result, the company’s current geographic footprint is best characterized as U.S.-centric with limited and non-core international exposure.

Leadership & Governance

cbdMD was founded by Martin Sumichrast, who played a key role in its early product development and public market entry. Leadership has evolved over time as the company navigated market volatility, with governance oversight provided by a board that includes business executives and former professional athletes. The company’s leadership philosophy has emphasized brand credibility, regulatory compliance, and disciplined capital management, particularly during recent restructuring phases.

Key executives and directors reported in recent public disclosures include:

• Isiah Thomas – Executive Chairman
• Martin Sumichrast – Founder and Director
• Jason Mitchell – Former Chief Executive Officer (role status varies by reporting period; current CEO designation is data inconclusive based on available public sources)
• Anna Richey – Chief Financial Officer

Management and board composition have experienced changes, and exact executive role assignments may differ across reporting periods. Where discrepancies exist, data is inconclusive based on available public sources.